^
Association details:
| Biomarker: | KIT wild-type |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | DS-6157 (Topoisomerase I inhibitor, GPR20 -targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Published date:
05/26/2022
Excerpt:
DS-6157a was generally well tolerated with early signs of moderate clinical activity. While there were no objective responses in pts with KIT-mutant GIST, tumor shrinkage was observed in all 4 pts with KIT wild-type GIST treated at different doses...
DOI:
10.1200/JCO.2022.40.16_suppl.11512
Trial ID:
